|
|
LATEST NEWS
INTERNATIONAL LIVER CONGRESS
EASL 2022
EASL Studio : Teatime
Picture EASL
Portal vein recanalisation alone to treat severe portal hypertension in non-cirrhotic patients with chronic extrahepatic portal vein obstruction
Artru F et al; JHEP Rep. 2022
In patients with technical success, 5-year primary patency was 73%, and was associated with improved muscle mass and decreased spleen volume at 1 year.
Prof Pierre-Emmanuel Rautou interviews the chairs of European and American guidelines on coagulation in liver diseases about the interest of anticoagulants in cirrhosis to improve patients' outcome
Contrast-enhanced CT and liver surface nodularity for the diagnosis of porto-sinusoidal vascular disorder: a case-control study
Shantha Ram Valainathan et al. - Hepatology - 2022
CT-scan to raise suspicion of Porto-Sinusoidal Vascular Disorder (PSVD):
- Liver Surface Nodularity and size of segment IV have a > 90% specificity for diagnosis of PSVD
- One more tool to help identify patients with this rare disease
A new video dedicated to patients, explaining portosinusoidal vascular disorders
Vascular Disorders of the Liver
|
VALDIG's Guide to Management and Causes
Link |
|
|
Multicenter study on recent portal venous system thrombosis associated with cytomegalovirus disease
Chloé De Broucker et al. - J. Hepatol - 2021
CMV disease triggers for portal vein thrombosis : => a special link with factor II gene mutation => do not forget to screen for all risk factors for thrombosis => no impact on recanalisation. For more details, please read our paper |
EASL TAKEWAYS - Cirrhosis and complications
Discover cirrhosis and complications with Professor Didier Samuel, Professor Andrés Cárdenas and Professor Pierre-Emmanuel Rautou
ERN Rare-Liver on-demand Webinar: Porto sinusoidal vascular disease
Podcast of Prof PE Rautou on porto-sinusoidal vascular disease : link
The International Liver Congress - EASL STUDIO
Prof U Beuers interviews Prof PE Rautou on porto-sinusoidal vascular disease
|
In the March 2021 issue of "Sciences et vie", multiomics are described in great detail. At this occasion, Prof. Pierre-Emmanuel Rautou explains the approach developed in the European project he coordinates, using omics to improve diagnosis and prognosis of patients with liver diseases : “C’est pourquoi nous avons lancé avec 20 autres centre européens un vaste projet d’analyse multiomique sur une cohort qui compte déjà 2200 patients.” 
|
Pierre-Emmanuel Rautou and Valerie Paradis obtained an ARC funding for the project "Endothelial autophagy in liver carcinogenesis related to NonAlcoholic Fatty Liver Disease : Role and potential therapeutic target"
|
|
Congratulations to Louise Biquard for her great award
EASL Digital ILC 2020 Takeaways - Cirrhosis and complications
The DECISION project coordinated by Prof Rautou
European researchers seek to reduce the number of patients dying from cirrhosis
Visite the website for more informations => here
European researchers seek to reduce the number of patients dying from cirrhosis
Visite the website for more informations => here
|
New Publication
Erythrocyte-derived microvesicles induce arterial spasms in JAK2V617F myeloproliferative neoplasm |
Our lab received the "EMERGENCE grant" by the city of Paris for the project “Predicting Outcome of patients with cirrhosis using circulating extracellular Vesicles”
|
Pierre-Emmanuel RAUTOU obtained the ATIP AVENIR funding which allows young scientists to create and lead a team within an established Inserm laboratory in France in January 2019
|
SPONSORS
|
|
|
|
|
|
|
|
|
|
|
|
|
Centre de recherche sur l'inflammation
UMR 1149 Inserm - Université de Paris
ERL CNRS 8252
Faculté de médecine site Bichat
16 rue Henri Huchard F-75018 Paris
UMR 1149 Inserm - Université de Paris
ERL CNRS 8252
Faculté de médecine site Bichat
16 rue Henri Huchard F-75018 Paris